Tirzepatide
A dual GIP and GLP-1 receptor agonist affecting appetite and glucose regulation.
What this compound is.
Tirzepatide is a dual agonist: it engages both the GIP and the GLP-1 receptor, two incretin pathways the body uses to regulate glucose and appetite. Acting on both is what distinguishes it from single-receptor agents in the same broad category.
Like semaglutide, it is studied in the specific clinical context of metabolic health, and is a prescription compound handled the same way as everything else here — provider-first.
How it has been studied.
Neutral notes on how this compound has been studied. These are not claims of safety or effectiveness, and not medical advice.
Studied clinically in the context of metabolic health, glucose regulation, and weight management.
Examined for engaging two incretin pathways (GIP and GLP-1) rather than one.
Reviewed for its appetite- and satiety-signaling effects.
Format, and what a provider weighs.
Prescribed formulations are typically administered by subcutaneous injection. Form and suitability are a provider's decision — nothing here is a recommendation, a protocol, or a dose.
- A provider reviews your metabolic and medical history and current medications before considering a prescription.
- Certain personal or family histories are contraindications a provider will screen for.
- Not appropriate during pregnancy or while breastfeeding. Availability varies by state.
Tirzepatide cannot be purchased directly on this site. It is available only after a licensed provider evaluates your intake and determines that treatment is clinically appropriate, and it is dispensed by a licensed compounding pharmacy. Eligibility is never guaranteed, and availability varies by state. See how it works and our approach to care.